{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:35:27Z","timestamp":1793086527873,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate whether quadrivalent human papillomavirus vaccine (4vHPV) administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. Insured women 13\u201327 years old with singleton pregnancies and a live birth from January 1, 2007, through September 1, 2013, who received 4vHPV during the periconceptional period (2 weeks before to 2 weeks after their last menstrual period), during pregnancy, or during both periods combined were compared with women who had a live birth during the same time period and received 4vHPV 4\u201318 months before their last menstrual period. We examined risks of gestational diabetes, hypertensive disorders of pregnancy, chorioamnionitis, preterm birth, small-for-gestational-age birth, and selected major structural birth defects in offspring. We estimated relative risks associated with receipt of 4vHPV during the periconceptional period, during pregnancy, and both exposure periods combined using a generalized linear model with Poisson distribution including a propensity score that included relevant maternal demographic and pregnancy characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of 92,579 potentially eligible pregnant women, 720 received 4vHPV during the periconceptional period, 638 received 4vHPV during pregnancy, and 8,196 received 4vHPV during the comparison period. Administration of 4vHPV during pregnancy was not associated with increased risk of adverse obstetric events, birth outcomes. Preterm birth occurred in 7.9% of pregnancies with vaccine exposures during pregnancy compared with 7.6% of pregnancies with vaccination in the comparison period (adjusted relative risk 0.97, 95% CI 0.72\u20131.3). Major structural birth defects were diagnosed in 2.0% of pregnancies with vaccine exposure during pregnancy compared with 1.8% of pregnancies with vaccine exposure during the comparison period (adjusted prevalence ratio 1.0, 95% CI 0.52\u20131.9). Results were similar for 4vHPV exposure during the periconceptional period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Quadrivalent HPV vaccine inadvertently administered in pregnancy or during the periconceptional period was not associated with adverse pregnancy or birth outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000002191","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T15:27:30Z","timestamp":1502206050000},"page":"599-608","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":37,"title":["Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy"],"prefix":"10.1097","volume":"130","author":[{"given":"Heather S.","family":"Lipkind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Vazquez-Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Romitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Naleway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin C.","family":"Hechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Hambidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse O.","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008","volume":"40","author":"Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R2-20261027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-20261027","doi-asserted-by":"crossref","first-page":"e1131","DOI":"10.1542\/peds.2014-2961","article-title":"The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts","volume":"135","author":"Smith","year":"2015","journal-title":"Pediatrics"},{"key":"R4-20261027","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"R5-20261027","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R6-20261027","first-page":"1","article-title":"Births: final data for 2014","volume":"64","author":"Hamilton","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"R7-20261027","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1097\/AOG.0000000000002052","article-title":"Human papillomavirus vaccination. Committee Opinion No. 704. American College of Obstetricians and Gynecologists","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R8-20261027","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2015.04.014","article-title":"Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine","volume":"33","author":"Goss","year":"2015","journal-title":"Vaccine"},{"key":"R9-20261027","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R10-20261027","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1612296","article-title":"Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes","volume":"376","author":"Scheller","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20261027","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1016\/j.vaccine.2015.07.024","article-title":"Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"33","author":"Baril","year":"2015","journal-title":"Vaccine"},{"issue":"suppl 1","key":"R12-20261027","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The Vaccine Safety Datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"key":"R13-20261027","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.vaccine.2013.03.069","article-title":"Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink","volume":"31","author":"Naleway","year":"2013","journal-title":"Vaccine"},{"key":"R14-20261027","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1016\/j.vaccine.2014.07.017","article-title":"Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events","volume":"32","author":"Nordin","year":"2014","journal-title":"Vaccine"},{"key":"R15-20261027","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.vaccine.2015.12.046","article-title":"Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007\u20132013","volume":"34","author":"Kharbanda","year":"2016","journal-title":"Vaccine"},{"key":"R16-20261027","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2014.14825","article-title":"Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes","volume":"312","author":"Kharbanda","year":"2014","journal-title":"JAMA"},{"key":"R17-20261027","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ypmed.2014.05.025","article-title":"Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites","volume":"67","author":"Kharbanda","year":"2014","journal-title":"Prev Med"},{"key":"R18-20261027","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.amepre.2015.08.017","article-title":"Influenza vaccination during pregnancy: influenza seasons 2002\u20132012, Vaccine Safety Datalink","volume":"50","author":"Groom","year":"2016","journal-title":"Am J Prev Med"},{"key":"R19-20261027","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2431-3-6","article-title":"A nearly continuous measure of birth weight for gestational age using a United States national reference","volume":"3","author":"Oken","year":"2003","journal-title":"BMC Pediatr"},{"key":"R20-20261027","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1136\/adc.2004.062810","article-title":"EUROCAT: 25 years of European surveillance of congenital anomalies","volume":"90","author":"Dolk","year":"2005","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"suppl 1","key":"R21-20261027","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/phr\/116.S1.32","article-title":"The National Birth Defects Prevention Study","volume":"116","author":"Yoon","year":"2001","journal-title":"Public Health Rep"},{"key":"R22-20261027","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/pds.4153","article-title":"Identifying birth defects in automated data sources in the Vaccine Safety Datalink","volume":"26","author":"Kharbanda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R23-20261027","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1001\/jama.2016.14432","article-title":"Tdap vaccination during pregnancy and microcephaly and other structural birth defects in offspring","volume":"316","author":"DeSilva","year":"2016","journal-title":"JAMA"},{"key":"R25-20261027","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.vaccine.2014.11.047","article-title":"Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013","volume":"33","author":"Moro","year":"2015","journal-title":"Vaccine"},{"key":"R26-20261027","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R27-20261027","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.acap.2014.03.005","article-title":"Uptake of human papillomavirus vaccine among adolescent males and females: Immunization Information System sentinel sites, 2009\u20132012","volume":"14","author":"Cullen","year":"2014","journal-title":"Acad Pediatr"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201709000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:00:27Z","timestamp":1793084427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201709000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002191","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}